ORIGINAL ARTICLE

Chronic obstructive pulmonary disease prevalence in Lisbon, Portugal: The burden of obstructive lung disease study

C. Bábara a, c, *, F. Rodrigues a, c, H. Dias a, d, J. Cardoso a, e, J. Almeida a, f, M. J. Matos a, g, P. Simão a, h, M. Santos a, i, J. R. Ferreira a, j, M. Gaspar k, L. Gnatius b, P. Burney b

a Advisory Board do Projeto Burden of Obstructive Lung Disease-Portugal, Sociedade Portuguesa de Pneumologia, Portugal
b National Heart and Lung Institute, Imperial College, London, UK
c Serviço de Pneumologia II, Centro de Estudos Doenças Crônicas, Hospital Pulido Valente, Centro Hospitalar de Lisboa Norte – E.P.E., Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal
d Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, Portugal
e Serviço de Pneumologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central – E.P.E., Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal
f Serviço de Pneumologia, Hospital de São João, Porto, Portugal
g Serviço de Pneumologia, Hospitais Universitários de Coimbra, Coimbra, Portugal
h Serviço de Pneumologia, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal
i Serviço de Pneumologia, Centro Hospitalar de Coimbra, Coimbra, Portugal
j Serviço de Pneumologia, Laboratório de Função Pulmonar, Hospital das Forças Armadas, Lisboa, Portugal
k Departamento de Medicina, Boehringer Ingelheim Lda., Lisboa, Portugal

Received 30 December 2011; accepted 7 November 2012

KEYWORDS
COPD prevalence; BOLD study; Burden of Obstructive Lung Disease; Airway obstruction

Abstract

Background: There is a great heterogeneity in the prevalence of Chronic Obstructive Pulmonary Disease (COPD) across the world. The Burden of Obstructive Lung Disease (BOLD) initiative was started to measure the prevalence of COPD in a standardized way. We aimed to estimate the prevalence of COPD in Portuguese adults aged 40 years or older of a target population of 2,700,000 in the Lisbon region, in accordance with BOLD protocol.

Methods: A stratified, multi-stage random sampling procedure was used which included 12 districts. The survey included a questionnaire with information on risk factors for COPD and reported respiratory disease and a post-bronchodilator spirometry performed at survey centres.

Results: For the 710 participants with questionnaires and acceptable spirometry, the overall weighted prevalence of GOLD stage I+ COPD was 14.2% (95% C.I. 11.1, 18.1), and stage II+ was 7.3% (95% C.I. 4.7, 11.3). Unweighted prevalence was 20.2% (95% C.I. 17.4, 23.3) for stage I+ and 9.5% (95% C.I. 7.6, 11.9) for stage II+. Prevalence of COPD in GOLD stage II+ increased with age and was higher in men. The prevalence of GOLD stage I+ COPD was 9.2% (95% C.I. 5.9, 14.0) in never smokers versus 27.4% (95% C.I. 18.5, 38.5) in those who had smoked ≥20 pack-years. The


* Corresponding author.
E-mail addresses: cristina.barbara@chln.min-saude.pt, cbarbara@netcabo.pt (C. Bábara).

2173-5115/$ - see front matter © 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.
agreement between previous doctor diagnosis and spirometric diagnosis was low, with 86.8% of underdiagnosed individuals.

Conclusions: The 14.2% of COPD estimated prevalence indicates that COPD is a common disease in the Lisbon region. In addition, a large proportion of underdiagnosed disease was detected. The high prevalence of COPD with a high level of underdiagnosis, points to the need of raising awareness of COPD among health professionals, and requires more use of spirometry in the primary care setting.

© 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.

---

**Prevalência da doença pulmonar obstrutiva crônica em Lisboa, Portugal: estudo burden of obstructive lung disease**

**Resumo**

*Introdução:* A prevalência da doença pulmonar obstrutiva crônica (DPOC) apresenta valores muito heterogéneos em todo o mundo. A iniciativa *Burden of Obstructive Lung Disease* (BOLD) foi desenvolvida para que a prevalência da DPOC possa ser avaliada com metodologia normalizada. O objetivo deste estudo foi estimar a prevalência da DPOC em adultos com 40 ou mais anos numa população alvo de 2 700 000 habitantes na região de Lisboa, de acordo com o protocolo BOLD.

**Métodos:** A amostra foi estratificada de forma aleatória multifaseada selecionando-se 12 freguesias. O questionário “até quanto fumo risco para a DPOC e doença respiratória autoreportada; adicionalmente, foi efetuada espirometria com provas de broncodilatação.

**Resultados:** Foram incluídos 710 participantes com questionário e espirometria aceitáveis. A prevalência estimada da DPOC na população no estádio GOLD I+ foi de 14,2% (IC 95%: 11,1; 18,1) e de 7,3% no estádio II+ (IC 95%: 4,7; 11,3). A prevalência não ajustada foi de 20,2% (IC 95%: 17,4; 23,3) no estádio I+ e de 9,5% (IC 95%: 7,6; 11,9) no estádio II+. A prevalência da DPOC no estádio GOLD II+ aumentou com a idade, sendo mais elevada no sexo masculino. A prevalência estimada da DPOC no estádio GOLD II+ foi de 9,2% (IC 95%: 5,9; 14,0) nos não fumadores versus 27,4% (IC 95%: 18,5; 38,5) nos fumadores com carga tabágica de ≥ 20 Unidades Maço Ano. Detetou-se uma fraqueza concordância entre a referência a diagnóstico médico prévio e o diagnóstico espirométrico, com 86,8% de subdiagnósticos.

**Conclusões:** O achado de uma prevalência estimada da DPOC de 14,2% sugere que esta é uma doença comum na região de Lisboa, contudo com uma elevada proporção de subdiagnósticos. Estes dados apontam para a necessidade de aumentar o grau de conhecimento dos profissionais de saúde sobre a DPOC, bem como a necessidade de maior utilização da espirometria nos cuidados de saúde primários.

© 2011 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.
by age, gender, and smoking status. Overall 20 countries have completed their study participation and other sites are in progress. The aim of our study was to estimate the prevalence of COPD based on a representative sample of non-institutionalized adults aged 40 years and over, carried out in Lisbon, Portugal, using standardized post-bronchodilator (post-BD) spirometry, as per the BOLD protocols.

Material and methods

We conducted a cross-sectional population survey following BOLD protocol, as described in detail elsewhere. Study fieldworkers were trained and certified in study methodology.

Sample size

A minimum sample size of 600 individuals was considered to provide an acceptable level of precision for prevalence estimates, assuming simple random sampling.

Study population

The survey was conducted among the residents of Lisbon region, whose population represents nearly 27% of the total Portuguese inhabitants, according to the 2007 census. The survey area was divided into two broad zones which are distinct regarding the demographic structure, socioeconomic status, population density and environmental stress: the inner city zone, with about 800,000 residents, and the suburbs with about 1,900,000 residents.

We used a stratified, multi-stage random sampling procedure. In the first sampling stage, 8 suburban and 4 inner-city districts were randomly selected from a total of 173 suburban and 53 inner-city districts of Lisbon. In the second sampling stage, households from the selected districts were randomly selected using a phone list that covered over 90% of the inhabitants of the districts selected. In the third sampling stage, individuals from the households selected were invited to participate if they were aged 40+. There was also a Minimal Data/Refusal questionnaire for participants who were not willing to participate in the full protocol (non responders). A professional survey-specialized phone-call centre was contracted to make contacts and invite participation. Data were collected between 16th of June and 7th of November 2008.

Of the 7123 individuals, whom we attempted to contact, 2776 agreed (over the phone) to take part in the survey. From those, 745 (27%) completed the protocol (core questionnaire plus post-BD spirometry), but 35 participants did not meet the American Thoracic Society (ATS) spirometry quality control criteria. Therefore, 710 responders (331 men and 379 women) constituted the final sample for this analysis (Fig. 1).

Written informed consent was obtained from each participant and ethics approval was granted by Ethics Committee.
of Hospital Pulido Valente and by the Portuguese Data Protection Authority.

**Spirometry**

At survey centres located in each county, pre and post-BD spirometry tests were performed according to the ATS guidelines by trained and certified technicians using the nddEasyOne™ Spirometer (ndd Medizintechnik; Zurich, Switzerland). At least three technically acceptable manoeuvres were performed, in a seated position, to obtain a minimum of two reproducible spirometry tests, with variability less than 200 mL, for both the forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC). Two puffs of salbutamol (200 μg) were administered with a metered dose inhaler connected to a spacer (15 cm length/2.1 cm diameter) and 20 min later the test (post-BD spirometry) was repeated. Spirometry tests were defined as acceptable, if they were free from artefacts, sudden stops, and back-extrapolated volumes greater than 5.0% of FVC or 150 mL, whichever was greater.

Spirometry data were sent electronically to the Pulmonary Function Quality Control Centre (Co-ordinating Centre in UK) where each spirometry was reviewed and graded according to its quality, based on criteria from the BOLD project. Study technicians were continuously monitored and if a technician’s quality-score dropped below a pre-set level, he/she had to stop testing and be re-trained and re-certified.

**Questionnaire data**

All participants answered BOLD questionnaires with demographic and clinical data, including doctor-diagnosed respiratory conditions.

The original BOLD questionnaires were translated from English to Portuguese and then back-translated to assure accuracy and conceptual equivalence. Questionnaires were obtained by face-to-face interview with trained and certified staff. A core questionnaire was completed for all individuals considered as responders. A minimal data/refusal questionnaire was collected from the non-responders group. Non-responders were eligible individuals who missed the core questionnaire and/or post-BD spirometry. By contrast responders completed both items. All the questionnaires were revised for completeness, accuracy and consistency within 48 hours of the interview by a team of seven certified physicians. All data were sent and quality controlled by the BOLD Co-ordinating Centre in UK.

**Definitions**

COPD was defined based on post-BD spirometry. In accordance with the Global Initiative for COPD (GOLD) guidelines, a not fully reversible airway obstruction was defined, as a post-BD FEV₁/FVC < 0.7. This definition was also used for COPD stage I+ in the analysis. Severity of COPD was defined as stage II+ if post-BD FEV₁ < 80% predicted, as stage III+ if post-BD FEV₁ < 50% predicted and stage IV if post-BD FEV₁ < 30%. Percent predicted values for Caucasian men and women were calculated using the National Health and Nutrition Examination Survey (NHANES) III reference equations.

COPD diagnosis was considered based on the post-BD lung function criteria without requiring the presence of symptoms or documented exposure to a known causative agent, as per BOLD protocol.

COPD doctor’s diagnosis (dx) was defined as the self-reported physician’s diagnosis of emphysema, chronic bronchitis or COPD.

Subjects were classified as current smokers, ever smokers or never smokers. Ever-smokers (including former and current smokers) were defined as individuals who smoke more than 20 packs of cigarettes in a lifetime or more than 1 cigarette per day during one year. The number of pack-years of cigarette smoking was defined as the average number of cigarettes smoked per day divided by 20 (i.e. packs per day) times the duration of smoking in years. Because of the low occurrence of stage IV COPD in the population samples, stages III and IV were combined in this paper.

**Statistical analysis**

This analysis included 710 Portuguese participants who completed the core questionnaire and who had acceptable post-BD spirometry measures. Results are presented stratified by gender, age-groups, pack-years smoked and as totals.

Prevalence estimates were calculated for the overall Lisbon population, as well as for subgroups defined by gender and either age or pack-years of cigarette smoking. Because the distribution of participants in the responders’ data differed slightly from that for Lisbon population, the data were weighted according to age and gender group, so that there would be a better match of the resulting prevalence estimates with those of Lisbon as a whole. In the weighting process each subject had a weight attached to him, where the weight corresponds to the number of people this subject represents in the population. The weighting was used in order to overcome limitations of sample survey, such as differential non-response rates, or under coverage of some sub-populations.

Weighted population-based estimates of COPD prevalence and their respective 95% confidence intervals (C.I.) were computed using survey data methods in STATA (STATA Corporation, College Station, TX, USA). These calculations were made to assure that the estimated prevalence and the respective 95% C.I. properly reflected the sampling design.

**Results**

Table 1 shows that there were no differences between responders and non-responders who completed minimal data questionnaire, except for gender, where non-responders were predominantly male.

Table 2 summarizes the main characteristics of the participants’ final sample. More than half of the subjects (63.0%) were 60 years or older and 53.4% were female. Current or former smoking was more frequent in men,
Table 1  Comparison of responders and non-responders for BOLD Portugal.*

<table>
<thead>
<tr>
<th></th>
<th>Responders&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Non-responders&lt;sup&gt;b&lt;/sup&gt;</th>
<th>p-Value&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>N = 745</td>
<td>N = 2026</td>
<td>.89</td>
</tr>
<tr>
<td></td>
<td>99 (13%)</td>
<td>252 (12%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>174 (23%)</td>
<td>473 (23%)</td>
<td></td>
</tr>
<tr>
<td>60–69</td>
<td>217 (29%)</td>
<td>581 (29%)</td>
<td></td>
</tr>
<tr>
<td>70+</td>
<td>255 (34%)</td>
<td>720 (36%)</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>349 (47%)</td>
<td>1086 (53%)</td>
<td>.002</td>
</tr>
<tr>
<td>Female</td>
<td>396 (53%)</td>
<td>944 (47%)</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>99 (13%)</td>
<td>30 (11%)</td>
<td>.18</td>
</tr>
<tr>
<td>Former</td>
<td>197 (26%)</td>
<td>65 (23%)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>449 (60%)</td>
<td>188 (66%)</td>
<td></td>
</tr>
<tr>
<td><strong>Doctor previous diagnosed asthma, emphysema, CB or COPD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>113 (15%)</td>
<td>33 (12%)</td>
<td>.15</td>
</tr>
<tr>
<td>No</td>
<td>630 (85%)</td>
<td>250 (88%)</td>
<td></td>
</tr>
<tr>
<td><strong>Other co-morbid conditions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>397 (53%)</td>
<td>159 (56%)</td>
<td>.41</td>
</tr>
<tr>
<td>No</td>
<td>348 (47%)</td>
<td>124 (44%)</td>
<td></td>
</tr>
</tbody>
</table>

* Values are given as No. (%).
<sup>a</sup> Responders are those who completed post-BD spirometry and the core questionnaire.
<sup>b</sup> Non-responders are eligible individuals who are missing the core questionnaire and/or post-BD spirometry, but for whom the tabulated variable is known.
<sup>c</sup> Two-sided p-value based on Pearson chi-square test.

Table 2  Characteristics of the study sample.*

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td>331 (47%)</td>
<td>379 (53%)</td>
<td>710 (100%)</td>
</tr>
<tr>
<td><strong>Age, yr</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>35 (11%)</td>
<td>61 (16%)</td>
<td>96 (14%)</td>
</tr>
<tr>
<td>50–59</td>
<td>74 (22%)</td>
<td>93 (25%)</td>
<td>167 (24%)</td>
</tr>
<tr>
<td>60–69</td>
<td>114 (34%)</td>
<td>91 (24%)</td>
<td>205 (29%)</td>
</tr>
<tr>
<td>70+</td>
<td>108 (33%)</td>
<td>134 (35%)</td>
<td>242 (34%)</td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>52 (16%)</td>
<td>42 (11%)</td>
<td>94 (13%)</td>
</tr>
<tr>
<td>Former</td>
<td>149 (45%)</td>
<td>41 (11%)</td>
<td>190 (27%)</td>
</tr>
<tr>
<td>Never</td>
<td>130 (39%)</td>
<td>296 (78%)</td>
<td>426 (60%)</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic cough</td>
<td>20 (6%)</td>
<td>54 (14%)</td>
<td>74 (11%)</td>
</tr>
<tr>
<td>Chronic phlegm</td>
<td>38 (11%)</td>
<td>55 (15%)</td>
<td>93 (13%)</td>
</tr>
<tr>
<td>Wheezing</td>
<td>86 (26%)</td>
<td>111 (29%)</td>
<td>197 (28%)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>51 (18%)</td>
<td>85 (29%)</td>
<td>136 (24%)</td>
</tr>
<tr>
<td><strong>Doctor diagnosed asthma, emphysema, chronic bronchitis or COPD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doctor diagnosed asthma</td>
<td>48 (15%)</td>
<td>60 (16%)</td>
<td>108 (15%)</td>
</tr>
<tr>
<td><strong>Doctor diagnosed COPD</strong></td>
<td>35 (11%)</td>
<td>47 (12%)</td>
<td>82 (12%)</td>
</tr>
<tr>
<td><strong>Doctor diagnosed COPD</strong></td>
<td>2 (1%)</td>
<td>2 (1%)</td>
<td>4 (1%)</td>
</tr>
<tr>
<td><strong>Other co-morbid conditions</strong></td>
<td>182 (55%)</td>
<td>192 (51%)</td>
<td>374 (53%)</td>
</tr>
</tbody>
</table>

* Values are given as No. (%).
while never smoking was more prevalent in women. Table 3 presents weighted population estimate of smoking habits by age and gender (unweighted data are shown in Table 3a of the electronic appendix). The prevalence of total current smokers was 17.9% (95% C.I. 12.5, 25.0). The highest current smoking prevalence occurred in the female 40–49 year age-group (33.1%, 95% C.I. 21.0, 48.0), decreasing with age. Among men, the highest prevalence was in the 50–59 year age-group. Ever smoking showed the highest prevalence in men aged 70+ years old.

Table 3 presents weighted population estimate of smoking habits by age and gender (unweighted data are shown in Table 3a of the electronic appendix). The prevalence of total current smokers was 17.9% (95% C.I. 12.5, 25.0). The highest current smoking prevalence occurred in the female 40–49 year age-group (33.1%, 95% C.I. 21.0, 48.0), decreasing with age. Among men, the highest prevalence was in the 50–59 year age-group. Ever smoking showed the highest prevalence in men aged 70+ years old.

Table 4a (electronic appendix) shows the unweighted estimated prevalence of COPD by gender and pack years as 20.2% (95% C.I. 17.4, 23.3) and 9.5% (95% C.I. 7.6, 11.9) respectively for COPD stage I+ and II+. Overall, the weighted estimated-population prevalence for GOLD stage I+ COPD was 14.2% (95% C.I. 11.1, 18.1), 18.7% (95% C.I. 12.6, 26.8) for males and 10.5% (95% C.I. 7.5, 14.7) for females (Table 4). In individuals reporting respiratory symptoms the estimated population prevalence for GOLD stage I+ COPD was higher, respectively 19.9% (95% C.I. 8.7, 39.3) for chronic cough, 21.7% (95% C.I. 13.1, 33.7) for chronic phlegm, 23% (95% C.I. 17.3, 29.8) for wheezing and 22.7% (95% C.I. 11.5, 39.9) for dyspnoea (data not shown). Concerning GOLD stage II+ COPD the estimated prevalence was 7.3% (95% C.I. 4.7, 11.3), and 1.4% (95% C.I. 0.23, 2.47) for GOLD stage III+, with higher levels in older people (70+ years: 5%); it was absent in the age group 40–49 years (Figs. 2 and 3).

According to Table 4, the population-estimated prevalence of GOLD stage I+ COPD was 9.2% (95% C.I. 5.9, 14.0) in participants who had never smoked and increased with the number of pack-years; it was 27.4% (95% C.I. 18.5, 38.5) in those with a smoking history of ≥20 pack-years. Similarly, the population-estimated prevalence of GOLD stage II+ COPD

### Table 3  Estimated-population prevalence of smoking habits by age and gender.∗

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Male</th>
<th>Ever smokers</th>
<th>Never smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49 yr</td>
<td>27.1 (20.6, 34.9)</td>
<td>57.7 (34.5, 77.9)</td>
<td>42.3 (22.1, 65.5)</td>
</tr>
<tr>
<td>50–59 yr</td>
<td>29.5 (12.8, 54.3)</td>
<td>67.6 (49.7, 81.4)</td>
<td>32.4 (18.5, 50.3)</td>
</tr>
<tr>
<td>60–69 yr</td>
<td>15.5 (8.3, 27.0)</td>
<td>53.0 (40.4, 65.3)</td>
<td>47.0 (34.7, 59.6)</td>
</tr>
<tr>
<td>70+ yr</td>
<td>11.0 (3.8, 28.1)</td>
<td>64.4 (50.5, 76.2)</td>
<td>35.6 (23.8, 49.5)</td>
</tr>
<tr>
<td>Total</td>
<td>22.1 (13.5, 34.1)</td>
<td>60.7 (54.3, 66.7)</td>
<td>39.3 (33.3, 45.7)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Female</th>
<th>Ever smokers</th>
<th>Never smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49 yr</td>
<td>33.1 (21.0, 48.0)</td>
<td>51.0 (34.4, 67.3)</td>
<td>49.0 (32.7, 65.6)</td>
</tr>
<tr>
<td>50–59 yr</td>
<td>12.3 (7.3, 19.9)</td>
<td>25.1 (13.1, 42.6)</td>
<td>75.9 (57.4, 86.9)</td>
</tr>
<tr>
<td>60–69 yr</td>
<td>7.0 (2.7, 16.7)</td>
<td>21.5 (15.4, 29.4)</td>
<td>78.4 (70.6, 84.6)</td>
</tr>
<tr>
<td>70+ yr</td>
<td>3.0 (1.0, 8.6)</td>
<td>13.5 (5.9, 27.9)</td>
<td>86.5 (72.1, 94.1)</td>
</tr>
<tr>
<td>Total</td>
<td>14.4 (10.0, 20.3)</td>
<td>28.3 (21.3, 36.6)</td>
<td>71.7 (63.4, 78.7)</td>
</tr>
</tbody>
</table>

∗ Weighted population estimate, with 95% confidence interval shown in parenthesis. Un-weighted data for the sample of responders are shown in the electronic appendix.

### Table 4  Estimated-population prevalence of COPD according to GOLD stage I+, GOLD stage II+ and doctor’s previous diagnosis by gender and pack-years.∗

<table>
<thead>
<tr>
<th>Stage</th>
<th>Never smokers %</th>
<th>0–10 pack-yr %</th>
<th>10–20 pack-yr %</th>
<th>20+ pack-yr %</th>
<th>Total %</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD stage I+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11.2 (5.5, 21.5)</td>
<td>19.8 (6.8, 45.4)</td>
<td>8.6 (2.2, 28.1)</td>
<td>27.9 (20.4, 40.0)</td>
<td>18.7 (12.6, 26.8)</td>
</tr>
<tr>
<td>Female</td>
<td>8.2 (4.5, 12.2)</td>
<td>5.0 (0.9, 22.9)</td>
<td>22.6 (6.3, 55.7)</td>
<td>26.0 (8.1, 58.3)</td>
<td>10.5 (7.5, 14.7)</td>
</tr>
<tr>
<td>Total</td>
<td>9.2 (5.9, 14.0)</td>
<td>11.5 (4.7, 25.4)</td>
<td>13.4 (6.4, 26.0)</td>
<td>27.4 (18.5, 38.5)</td>
<td>14.2 (11.1, 18.1)</td>
</tr>
<tr>
<td>GOLD stage II+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3.7 (1.4, 9.6)</td>
<td>3.6 (0.7, 17.0)</td>
<td>3.3 (0.5, 18.1)</td>
<td>17.2 (8.6, 31.5)</td>
<td>9.1 (4.4, 17.7)</td>
</tr>
<tr>
<td>Female</td>
<td>4.6 (2.7, 7.6)</td>
<td>3.3 (0.7, 14.6)</td>
<td>22.6 (6.3, 55.7)</td>
<td>10.4 (3.5, 27.2)</td>
<td>5.8 (3.8, 8.8)</td>
</tr>
<tr>
<td>Total</td>
<td>4.3 (2.6, 7.1)</td>
<td>3.4 (1.3, 8.6)</td>
<td>9.9 (3.4, 25.4)</td>
<td>15.4 (7.9, 27.8)</td>
<td>7.3 (4.7, 11.3)</td>
</tr>
<tr>
<td>Doctor’s previous diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.3 (0.4, 4.3)</td>
<td>3.5 (0.4, 23.2)</td>
<td>21.3 (5.0, 58.2)</td>
<td>9.8 (5.1, 18.1)</td>
<td>6.8 (3.8, 11.8)</td>
</tr>
<tr>
<td>Female</td>
<td>5.0 (3.1, 8.1)</td>
<td>8.4 (3.6, 18.3)</td>
<td>10.9 (3.1, 32.2)</td>
<td>6.0 (1.6, 20.3)</td>
<td>5.8 (4.4, 7.6)</td>
</tr>
<tr>
<td>Total</td>
<td>3.9 (2.2, 6.7)</td>
<td>6.2 (2.4, 15.0)</td>
<td>17.1 (4.8, 45.7)</td>
<td>8.8 (5.9, 12.9)</td>
<td>6.3 (4.7, 8.3)</td>
</tr>
</tbody>
</table>

∗ Weighted population estimate, with 95% confidence interval shown in parenthesis. Un-weighted data for the sample of responders, are shown in the electronic appendix.
The overall prevalence of GOLD-defined COPD was higher in men than in women. COPD prevalence increased with age and smoking habits, with the highest estimated prevalence in men (47.2%) 70+ years old. Our data also support a high level of underdiagnosis (86.8%) and an unexpected high prevalence (9.2%) in never smokers.

It is necessary to quantify COPD prevalence, so as to document the effects of COPD effects on disability, quality of life and health care costs, and also to inform governments and public health authorities in planning to meet the growing demand for services. The BOLD initiative was developed standardized methods for estimating COPD prevalence and for obtaining data about risk factors. The first BOLD report of COPD prevalence across the world showed heterogeneity between countries and genders. Moreover, the reported prevalence tended to be greater than those previously known.

The Lisbon BOLD survey is the first Portuguese study about COPD prevalence with a standardized methodology implemented internationally allowing comparison across countries. The main strength of this survey was the use of BOLD protocol, with a rigorous methodology to achieve the maximum accuracy and completeness of the survey and a high-quality post-BD spirometry. This methodology ensured that data were as easy to compare as possible with other BOLD studies.

The reported low response rate (27%) of our study was one of the main limitations; this can be justified as a reactive attitude of participants to the high number of calls made by marketing companies in Portugal. Nevertheless, our response rate was similar to other published data sites (Vancouver and Kentucky), which also used random-digit-dialling.

In order to make sure that the studied sample was representative of the whole target population, a minimal data questionnaire was collected from the non responders, making it possible to compare both groups (responders/non
responders). Except for gender, there were no differences between the groups in relation to age, risk factors and clinical profile. To deal with the high non-response rate and also gender differences, more telephone contacts were made to obtain data from at least 300 females and 300 males. In addition, in order to overcome the potential for response bias, we used weighting for the adjustment of prevalence to the target population. 

Before the BOLD results became available, Portuguese official prevalence of COPD was 5.34%, based on a study from 2002. 

Portugal Lisbon BOLD data revealed a higher value of COPD prevalence (14.2%). So far, all the projections and health planning regarding COPD have been based on the previous prevalence figures meaning that the real burden of COPD has been underestimated.

Because the two studies used different methodologies, their results should not be compared. 

Regarding the 2002 study, there were some methodological issues that make comparison impracticable. In fact, this study used a different source population, a restrictive sample in relation to age range and also different COPD diagnosis criteria (without post-BD spirometry) and reference equations.

Comparing our data to the international BOLD studies we conclude that Portuguese COPD prevalence is lower than many countries prevalence, although similar to the prevalence of some European countries like Germany (13.2%) and Sweden (16.2%). These differences could be attributed to different levels of smoking in the population, or possibly other risk factors, which are not analyzed here and might need further investigation (e.g. occupation, biomass, air pollution).

In our study, NHANES III equations were used to estimate the prevalence of COPD Stage II+, in order to allow comparisons between countries. However it should be noted that the choice of the right setting of predicted equations is a matter of debate and might influence prevalence estimates.

Our data showed that COPD prevalence increases with age, being higher above 70 years old. It is worth noting that, with ageing, the prevalence in men becomes twice the prevalence in women of the same age group, probably reflecting ever smoking prevalence that corresponds to the cumulative effect of tobacco. Taking into account that COPD stage I+ is defined by the fixed ratio FEV1/FVC, and that this ratio falls with age in healthy individuals, the high prevalence found in older people could also represent over diagnosis (47.2% in stage I+ versus 17.2% in stage II+). Nevertheless, we still found the same tendency for age related increase in COPD prevalence in stage II+, although less pronounced.

In the group of females with 10–20 pack-yr the prevalence is exactly the same for GOLD stage COPD I+ and II+ (Table 4), meaning that, in our sample, there were no women in the group with a FEV1/FVC < 70% and FEV1 > 80% predicted. Although unusual, this data was double-checked and confirmed.

As found in other studies, there was also a positive trend with the increasing of pack-years, confirming smoking as an important risk factor for the development of the disease. In fact, above 20 pack-years COPD prevalence doubles (27.4% versus 14.2%), representing an even higher burden of healthcare resources utilization and costs.

Another important issue of this study was the estimate of 17.9% for the prevalence of current smoking in Portuguese people older than 40 years old. This data is consistent with the official prevalence data (17.2%) from the National Health survey of 2005/2006. The highest prevalence of smoking habits found in younger women (40–49 years) strengthens the future projection of an increase of COPD in women, and also the need to target teenagers and young women in smoking cessation campaigns. Concerning never smokers, an unexpected COPD prevalence of 9.2% was found, suggesting a possible overdiagnosis by spirometric parameters. Nevertheless, the COPD prevalence of 4.3% for stage II+, could be the expression of other risk factors that should also be investigated (e.g. biomass exposure, childhood respiratory tract infections, past tuberculosis). Moreover in some people, this high prevalence might indicate asthma with remodelling in the small airways. Similar findings have been described in other countries.

The finding of higher levels of COPD prevalence in symptomatic subjects than in the general population was also expected and the need for a spirometry should be brought to the attention of primary care physicians.

In this study, a gap was found between the presence of airflow obstruction defined by GOLD criteria and doctor’s diagnosis. Overall, only 6.3% of the participants reported COPD doctor’s diagnosis, while GOLD stage I+ registered 14.2%. Moreover, the difference is even greater if we base our analysis on the degree of concordance between COPD doctor diagnosis and spirometric diagnosis. In fact, only 13.2% of spirometrically diagnosed COPD had been previously diagnosed (underdiagnosis). These data are consistent with those of Spain where, despite an eventual decrease in COPD prevalence, there are still high levels of underdiagnosis. Furthermore, 61.2% of the reported cases of COPD” declared by the participants to have been “doctor diagnosed” were not confirmed by spirometry (overdiagnosis). These numbers clearly show a high degree of COPD misdiagnosis and highlight the urgency to improve physicians’ knowledge about COPD diagnosis, and the need to emphasize the use of spirometry, particularly with symptomatic subjects.

Conclusions

The 14.2% estimated-prevalence indicates that COPD is a common disease in the Lisbon region. The high prevalence of COPD with a large proportion of undiagnosed disease, highlights the importance of raising awareness of COPD among health professionals, and requires more use of spirometry in the primary care setting. Despite ageing and smoking remain major risk factors for COPD, other risk factors contributing to the presence of disease in never smokers should be investigated in future studies.

Funding

The BOLD project in Portugal was conducted by the Respiratory Portuguese Society to the Co-ordinating Centre located at the Imperial College, UK and funded by Boehringer Ingelheim and Pfizer.
Conflicts of interest

The BOLD project in Portugal was conducted by the Respiratory Portuguese Society to the Co-ordinating Centre located at the Imperial College, UK and funded by Boehringer Ingelheim and Pfizer.

Acknowledgments

The BOLD investigators would like to thank:

- Sonia Buist (Oregon Health and Sciences University, Portland, OR, USA), William Vollmer, Mary Ann McBurnie and Suzanne Gillespie (Kaiser Permanente Center for Health Research, Portland, OR, USA) and Robert Jensen ( Latter Day Saints Hospital, Salt Lake City, UT, USA) for all the support to Fátima Rodrigues and Herminia Dias in BOLD protocol, including questionnaires and spirometry certification and questionnaires validation for Portuguese language.
- The UK Co-ordinating Centre staff particularly Richard Hooper, Anamika Jithoo; and Sonia Coton.
- The certified interviewers: Ana Bandarra, Andreia Machado, João Silva, Tânia Fonseca and Ângela Antunes.
- The certified physicians: Inês Faria, Ana Sofia Oliveira, Márcia Man, Patricia Garrido, Ana Margarida Alves and Susana Carreira, who participated with Fátima Rodrigues in the revision of questionnaires and submission of data to BOLD UK Centre.
- The certified cardiopulmonology technicians: Ana Cristina Lutas, Ana Sofia Cachola, Andrea Carina de Jesus Colaço, Andrea Descalço, Cátia Ligia Oliveira, Cláudia Pereira, Daniela Ricardo, Joana Quaresma, Marta Landeiro, Sara Matos, Sara Serranho and Susana Filipa Gomes Marcelino, from Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa.

BOLD investigators would also like to thank Prof. Doutor António Gouveia for the statistical support and Carlos Capela, as sponsor project leader, and everybody at Boehringer Ingelheim Portugal and Pfizer who were involved and collaborated in this project.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.rppneu.2012.11.004.

References

